Innovative Medicine was the largest of Johnson & Johnson’s 2 reported lines in fiscal 2023, at $27.79B — 65% of $42.70B.
| Segment | FY 2009 | FY 2009 | FY 2009 | FY 2010 | FY 2010 | FY 2010 | FY 2011 | FY 2011 | FY 2011 | FY 2012 | FY 2012 | FY 2012 | FY 2013 | FY 2013 | FY 2013 | FY 2014 | FY 2014 | FY 2014 | FY 2015 | FY 2015 | FY 2015 | FY 2016 | FY 2016 | FY 2016 | FY 2017 | FY 2017 | FY 2017 | FY 2018 | FY 2018 | FY 2018 | FY 2019 | FY 2019 | FY 2019 | FY 2022 | FY 2022 | FY 2022 | FY 2023 | FY 2023 | FY 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Innovative Medicine | $25.74B | $26.63B | $26.43B | $26.83B | $27.46B | $27.79B | |||||||||||||||||||||||||||||||||
| Pharmaceutical | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| Medtech | $13.94B | $13.80B | $13.56B | $14.96B | $15.58B | $14.92B | |||||||||||||||||||||||||||||||||
| Med Devices | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| Medical Devices | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| Medical Devices & Diagnostics | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| Consumer | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||
| Total | $39.68B | $40.43B | $39.99B | $41.79B | $43.04B | $42.70B |
In fiscal 2023, which ended October 1, 2023, the 2 segments Johnson & Johnson reported in this breakdown added up to $42.70B. That was down 0.8% from $43.04B in fiscal 2023. Innovative Medicine was the largest segment, at $27.79B or 65.1% of the total, followed by Medtech ($14.92B, 34.9%).
Compared with fiscal 2023, Innovative Medicine grew the fastest, rising 1.2% to $27.79B. Medtech fell the most, down 4.2% to $14.92B.
The table also keeps 5 segments that Johnson & Johnson no longer reports, so earlier years can still be read on their original basis; use "Show 5 discontinued" beneath the table to see them. This breakdown covers 39 fiscal years between 2009 and 2023, as reported in Johnson & Johnson's annual filings.
United States was the largest of Johnson & Johnson’s 4 reported lines in fiscal 2017, at $79.73B — 52% of $152.90B.
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2012 | FY 2013 | FY 2014 | FY 2016 | FY 2017 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Segments | — | — | $143.78B | — | |||||
| United States | $69.56B | $71.37B | — | $79.73B | |||||
| U S | — | — | — | — | |||||
| Europe | $37.89B | $31.99B | — | $34.25B | |||||
| Asia-Pacific, Africa | $26.88B | $24.69B | — | $26.84B | |||||
| Segment, Geographical, Groups Of Countries, Group Two | — | — | — | — | |||||
| Segment Geographical Groups Of Countries Group Two | — | — | — | — | |||||
| Western Hemisphere Excluding U.S | $14.32B | $12.09B | — | $12.08B | |||||
| Western Hemisphere, Excluding U.S | — | — | — | — | |||||
| Segment, Geographical, Groups Of Countries, Group One | — | — | — | — | |||||
| Segment Geographical Groups Of Countries Group | — | — | — | — | |||||
| Total | $148.66B | $140.15B | $143.78B | $152.90B |
In fiscal 2017, which ended December 31, 2017, the 4 regions Johnson & Johnson reported in this breakdown added up to $152.90B. The regions reported changed from fiscal 2017, so the total is not directly comparable with the $143.78B reported that year. United States was the largest region, at $79.73B or 52.1% of the total, followed by Europe ($34.25B, 22.4%) and Asia-Pacific, Africa ($26.84B, 17.6%). Together, the two largest regions made up 74.5% of this total.
Over fiscal 2014 to 2017, revenue across these regions went from $148.66B to $152.90B, a compound annual growth rate of 0.9%. United States' share of the total rose from 46.8% to 52.1% over the same years.
The table also keeps 7 regions that Johnson & Johnson no longer reports, so earlier years can still be read on their original basis; use "Show 7 discontinued" beneath the table to see them. This breakdown covers 9 fiscal years between 2010 and 2017, as reported in Johnson & Johnson's annual filings.
Johnson & Johnson (JNJ) breaks its revenue down by segment and region. In fiscal 2023, its largest segment was Innovative Medicine, with $27.79B or 65.1% of the total, followed by Medtech at $14.92B (34.9%).
Innovative Medicine was Johnson & Johnson's largest segment in fiscal 2023, with $27.79B in revenue, 65.1% of the $42.70B reported across its 2 segments.
United States was Johnson & Johnson's largest region in fiscal 2017, with $79.73B in revenue, 52.1% of the $152.90B reported across its 4 regions.
Every figure is taken from Johnson & Johnson's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by segment covers fiscal 2009 to 2023. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.